The hot new trend in weight loss is Ozempic, a weekly injection which is helping people lose unwanted pounds.  Ozempic is known as a diabetes drug which a side effect was weight loss.  Looks like now there could be competition on the way from a drug from pharmaceutical giant Novo Nordisk in the form of a pill.

Heavyweight Man Eating Funk Food
Getty Images
loading...

 

In a clinical trial, participants taking Novo Nordisk's experimental weight loss treatment amycretin lost 13% of their weight over 12 weeks. Amycretin is a pill that targets the same GLP-1 hormone as other weight loss drugs like Novo's Wegovy and Lilly's Zepbound. It also stimulates another hormone, amylin, which regulates hunger.

Demand Surges For Weight Loss Drug Ozempic
Getty Images
loading...

These results, although not yet published or subject to external scientific scrutiny, exceed weight loss from its blockbuster drug Wegovy, which resulted in around 6% weight loss at 12 weeks. Novo Nordisk stated that amycretin appeared to be safe and well-tolerated, with a similar side effect profile to its other medicines in the field like semaglutide, the injectable GLP-1 drug sold as Ozempic for diabetes, and Wegovy for weight loss.

Fox Sports 1510 logo
Get our free mobile app
Appeals Court Keeps Abortion Pill Mifepristone Available, But With Restrictions
Getty Images
loading...

Although the trial was small, Novo Nordisk's head of development, Martin Lange Holst, said that the promising results justify further research into the pill. He also mentioned that Novo Nordisk would proceed with the drug and start a larger Phase 2 trial in the second half of this year. Results are expected to be released in early 2026.

Novo Nordisk is also testing a subcutaneous form of amycretin that, like Wegovy, would be delivered by regular injection. The early-stage trial is ongoing, and data could be released in 2025.